高盛-百济神州(688235):业绩回顾:一季度业绩超预期,指引上调,聚焦ASCO明确实体瘤管线前景-Earnings Review:1Q beat with upgraded guidance;eyes on ASCO for solid tumor pipeline visibility-20260507【9页】

发表回复

后才能评论